Danaher Corporation $DHR Shares Sold by Cooper Investors PTY Ltd.

Cooper Investors PTY Ltd. reduced its holdings in shares of Danaher Corporation (NYSE:DHR) by 18.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,694 shares of the conglomerate’s stock after selling 6,741 shares during the quarter. Danaher accounts for 2.3% of Cooper Investors PTY Ltd.’s portfolio, making the stock its 17th largest position. Cooper Investors PTY Ltd.’s holdings in Danaher were worth $7,026,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. JPL Wealth Management LLC acquired a new position in shares of Danaher during the 3rd quarter valued at $25,000. WFA of San Diego LLC acquired a new stake in Danaher in the 2nd quarter valued at $26,000. ANTIPODES PARTNERS Ltd purchased a new position in Danaher in the third quarter valued at about $27,000. Howard Hughes Medical Institute purchased a new position in Danaher in the second quarter valued at about $27,000. Finally, TruNorth Capital Management LLC acquired a new position in shares of Danaher during the third quarter worth about $28,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.1%

Shares of NYSE:DHR opened at $181.65 on Monday. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. The company has a fifty day simple moving average of $209.30 and a 200 day simple moving average of $214.70. The firm has a market cap of $128.55 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 2.46 and a beta of 0.93. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The firm had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.14 EPS. On average, equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio is 31.75%.

Insider Buying and Selling

In related news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the transaction, the executive vice president directly owned 5,099 shares in the company, valued at approximately $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. HSBC upped their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Morgan Stanley started coverage on Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 price target on the stock. Jefferies Financial Group upped their price target on Danaher from $255.00 to $265.00 and gave the stock a “buy” rating in a report on Wednesday, January 28th. Robert W. Baird set a $251.00 price objective on shares of Danaher in a research report on Thursday, January 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Danaher in a research note on Wednesday, January 7th. Nineteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $253.55.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.